Bioavailability (BA) is defined as the rate and extent to which the unchanged active substance is absorbed and becomes available in the systemic circulation. Understanding bioavailability is essential during drug development as it is one of the fundamental properties of drug formulation. Information on bioavailability is also used to determine bioequivalence (BE) when submitting a generic dossier.
Through interactive sessions and multiple case studies this 2-day course will evaluate every aspect of BA/BE from the regulations and types of protocol studies to bioanalysis, statistical analysis and reporting. Once completed you will have a solid understanding of bioavailability, supporting you in drug development. You will also have the confidence to develop and implement your own bioequivalence studies to ensure speedy generic approval.
The course will also examine key aspects of biowaivers such as the regulatory hurdles, types of biowaivers and data needed so you can save money and time with fast biowaiver applications.
This course is designed for professionals working in the following areas:
Jean-Michel Cardot is a professor and Head of the Department of Biopharmaceutics and Pharmaceutical Technology at the Universite d’Auvergne, France. His laboratory research fields are dissolution, bioequivalence and IVIVC. His personal research fields are biopharmaceutical development of drugs, in vivo bioequivalence and IVIVC.
To find out more about Jean-Michel Cardot, you can watch 'Meet our Trainers' video featuring Jean-Michel on our YouTube channel by clicking here.
"The course itself was extensive and broad. The trainer had an excellent ability to communicate."
Director, Regivet BV
"I chose this course to support my knowledge collected by 'learning by doing' with facts and additional background. The course was very interactive and the trainer had a great amount of knowledge."
Head of Clinical Development & Drug Safety, AOP Orphan Pharmaceuticals
"The bioanalytical part, regulatory tips and in vitro parts are the aspects of the course I enjoyed the most." Project Lead, Tecnimede S.A.
"This was the only in-depth course on Bioequivalence I could find. The knowledge and experience of the trainer was excellent. There were a lot of practical examples given including issues which I had encountered in the past."
Regulatory Affairs Development Manager, Regivet BV
We're looking forward to welcoming our attendees and expert course leaders at Bioavailability and Bioequivalence in London in May.
Our number one priority is the safety of our delegates and colleagues, and there are always measures in place at our venues to safeguard your health and safety. There are extra measures in place for 2020 in light of developments with COVID-19.
Book with total confidence – click here to be fully assured on how your booking rights are protected.
The trainer was very experienced with many examples and encouraged time for questions.
The trainer was very knowledgeable and had good presentation skills.
The knowledge of the trainer was excellent. There were a lot of practical examples given including issues which I had encountered in the past.